THE ASSEMBLY: A QUIET CORNERSTONE OF PROGRESS AND WHY THIS
WORK MATTERS
Within the American Psychiatric Association, the Assembly holds a
role that is essential but often complex and difficult to interpret;
therefore, explaining its role in advancing change is not always
straightforward. It is the primary democratic engine that translates the
concerns of members, the needs of patients and families, and the
emerging realities of clinical practice into actionable policy. While
the Assembly is well established as a deliberative and effective body,
many members engage with it only peripherally, and even fewer fully
appreciate its scope, its influence, and the rigor behind its
processes.
The Assembly is where frontline experience meets organizational
leadership. It is where scientific advancement is discussed alongside
the practical challenges of implementation, and where ideas are refined
through a structured, respectful, and evidence informed process. This
system functions because of a thoughtful balance between bottom-up
representation and top down guidance, a mechanism that allows the most
pressing clinical, ethical, and policy concerns to surface, to be
debated, and ultimately to shape the direction of the organization. The
work is deliberate, sometimes slow, but always principled. It
incorporates the soft accents of diplomacy, consensus building, and
collegiality while maintaining the necessary resolve to confront complex
issues.
Over the past two years, my participation in the Assembly paired with
the dedicated partnership of Dr. Christine Marchionni has underscored
how essential this process is. Through sustained dialogue, careful
analysis, and collaboration across caucuses, we have worked to bring
forward issues that affect our patients, families, colleagues, and the
evolving identity of psychiatry. This work has culminated in the
submission of nine action papers that address scientific, clinical, and
policy challenges of national relevance. These include:
-
Reducing Access to Lethal Means: Restricting Acetaminophen Pack
Size (ASMNOV2312.F) -
Advancement of New Research: Triple Blind Peer Review in APA
Publications (ASMMAY2412.F) -
Two Decades Post FDA Box Warning on SSRIs: Call for Review
(ASMMAY2412.G) -
Prioritize Clinical Diagnosis Over Neuropsychological Testing for
ASD (ASMNOV2412.G) -
Critical Review of Suicide Risk Assessments: Moving Beyond
Traditional Low, Moderate, and High (ASMNOV2412.F) presented again and
passed as (ASMMAY2512.G) -
The Influence of Online Reviews on Psychiatric Practice
(ASMMAY2512.A) -
FDA Approval Does Not Equate to APA Endorsement
(ASMMAY2512.H) -
Safeguarding Human Intelligence in Medical Decision Making Amidst
the Rise of Artificial Intelligence (ASMMAY2512.I)
Each paper reflects a broader commitment to ensuring that evidence
informs policy, that clinical realities shape organizational practice,
and that psychiatry remains responsive to the shifting needs of its
membership and the communities we serve. These submissions highlight an
important truth: meaningful change is not the product of isolated
actions but of ongoing participation. It requires members to bring
forward ideas, coauthor proposals, debate constructively, and trust the
Assembly as a venue where divergent perspectives can converge into
thoughtful solutions.
In the recently concluded Assembly sessions, also successfully passed
two additional action papers co-authored with our Assembly colleagues:
Neuroscience-Based Nomenclature for Psychiatric
Medications (Item 2025A2 12.B), co-authored with Drs.
Randall Gurak, Adam Tripp, Farooq Mohyuddin, and Mujahid Ali Syed; and
Pharmacogenetic Testing in Psychiatry: Evidence-Based
Guidance (Item 2025A2 12.C) co-authored with Drs. Farooq
Mohyuddin, Narpinder Malhi, Hector Colon-Rivera, and Mujahid Ali
Syed.
Pennsylvania has often been at the forefront of this work, advancing
conversations that have resonated on the national stage and helping
shape substantive reforms. The past two years have been deeply
rewarding, not because the process is easy, but because it reveals how
collective effort can meaningfully influence the field. The Assembly
continues to operate as a model of constructive governance: respectful
in tone, rigorous in method, and unwavering in its dedication to
patients and families.
As we look ahead, my hope is simple. More members will engage with
this process, offer ideas, and participate in shaping the future of our
profession. The vitality of the Assembly and the relevance of psychiatry
itself depend on ongoing collaboration, continuous learning, and a
shared commitment to advancing both science and humanity.
In that spirit, it is with great pride and enthusiasm that Dr.
Christine Marchionni and I have been nominated for the Warren Williams
Assembly Speaker’s Award. This recognition reflects the collective
strength of our district branch and the Assembly process itself. It is a
testament to what is possible when advocacy, scholarship, and
organizational leadership come together.
The work continues, and we invite each of you to be part of it.
About Dr. Mayank Gupta
About Dr. Mayank Gupta, MD, DFAPA, DFAACAP, CPE
Dr. Mayank Gupta is a Triple Board-Certified Psychiatrist and
Distinguished Fellow of the American Psychiatric Association and the
American Academy of Child and Adolescent Psychiatry. A long-standing
leader within organized psychiatry, President of the Pittsburgh
Psychiatric Society, and is an active contributor to the APA Assembly,
where he has advanced evidence-based policy and clinical advocacy.
Internationally trained and nationally recognized, Dr. Gupta
completed psychiatric training in London at the Charing Cross Program
before completing residency at New York Medical College and a Child and
Adolescent Psychiatry fellowship at Rutgers University. He is also
certified in Addiction Medicine and a Certified Physician Executive.
Dr. Gupta’s leadership has spanned inpatient, outpatient, and system
wide roles, including service during pandemic to expand rural access to
youth mental health care earned him the APA’s William C. Menninger
Memorial Award for Rural Psychiatry.
A committed advocate for scientific rigor and patient centered care,
Dr. Gupta has authored numerous scholarly publications and continues to
contribute to APA initiatives, action papers, and national policy
discussions. His clinical work integrates developmental science,
psychotherapy, and neuropsychopharmacology, reflecting his dedication to
advancing psychiatry in service of patients, families, and the
profession.